WINTON GROUP Ltd Invests $965,000 in Astrazeneca Plc $AZN

WINTON GROUP Ltd bought a new position in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 5,500 shares of the company’s stock, valued at approximately $965,000.

A number of other large investors have also recently made changes to their positions in the business. Bank of Montreal Can boosted its stake in shares of Astrazeneca by 344.6% during the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after purchasing an additional 2,695,793 shares during the period. Holocene Advisors LP boosted its stake in shares of Astrazeneca by 41.8% during the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after purchasing an additional 1,807,565 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Astrazeneca by 11,190.9% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after purchasing an additional 1,790,874 shares during the period. Raymond James Financial Inc. boosted its stake in shares of Astrazeneca by 64.8% during the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after purchasing an additional 1,487,662 shares during the period. Finally, Bank of America Corp DE grew its stake in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Stock Performance

AZN opened at $183.36 on Wednesday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a market cap of $284.38 billion, a price-to-earnings ratio of 27.53, a PEG ratio of 1.56 and a beta of 0.25. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The firm’s fifty day simple moving average is $190.49 and its two-hundred day simple moving average is $185.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Equities analysts anticipate that Astrazeneca Plc will post 9.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Finally, Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and an average price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.